THMO Stock Overview
Develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ThermoGenesis Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0006 |
| 52 Week High | US$1.25 |
| 52 Week Low | US$0.0005 |
| Beta | 2.49 |
| 1 Month Change | -14.29% |
| 3 Month Change | -99.74% |
| 1 Year Change | -99.90% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks
Apr 17
ThermoGenesis reports Q2 results
Aug 11Is ThermoGenesis Holdings (NASDAQ:THMO) Using Too Much Debt?
Oct 20Is ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?
May 31When Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?
Apr 06Here's Why ThermoGenesis Holdings (NASDAQ:THMO) Can Afford Some Debt
Feb 10Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?
Dec 15
ThermoGenesis EPS misses by $0.27, misses on revenue
Nov 12Shareholder Returns
| THMO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 20.0% | -1.5% | -2.4% |
| 1Y | -99.9% | 10.0% | 23.4% |
Return vs Industry: THMO underperformed the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: THMO underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| THMO volatility | |
|---|---|
| THMO Average Weekly Movement | 958.9% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: THMO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: THMO's weekly volatility has increased from 433% to 959% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 25 | Chris Xu | www.thermogenesis.com |
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications.
ThermoGenesis Holdings, Inc. Fundamentals Summary
| THMO fundamental statistics | |
|---|---|
| Market cap | US$9.51k |
| Earnings (TTM) | -US$14.74m |
| Revenue (TTM) | US$9.61m |
0.0x
P/S Ratio0.0x
P/E RatioIs THMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THMO income statement (TTM) | |
|---|---|
| Revenue | US$9.61m |
| Cost of Revenue | US$7.58m |
| Gross Profit | US$2.03m |
| Other Expenses | US$16.77m |
| Earnings | -US$14.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 21.10% |
| Net Profit Margin | -153.43% |
| Debt/Equity Ratio | -386.9% |
How did THMO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:02 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ThermoGenesis Holdings, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Jon Hickman | MDB Capital Group LLC |